Therapeutic exploitation of oncolytic viruses in pediatric oncology

• Verfasst von: Lacroix, Jeannine [VerfasserIn]
• Verfasst von: Witt, Olaf [VerfasserIn]
• Verfasst von: Schlehofer, Jörg R. [VerfasserIn]
• Verfasst von: Rommelaere, Jean [VerfasserIn]
• Titel: Therapeutic exploitation of oncolytic viruses in pediatric oncology
• Verf.angabe: J. Lacroix, O. Witt, J.R. Schlehofer and J. Rommelaere
• Jahr: 2010
• Umfang: 13 S.
• Fussnoten: Gesehen am 09.03.2023
• Titel Quelle: Enthalten in: Drugs of the future
• Ort Quelle: [Philadelphia, PA] : Clarivate Analytics, 1976
• Jahr Quelle: 2010
• Band/Heft Quelle: 35(2010), 12, Seite 1015-1027
• ISSN Quelle: 2013-0368
• DOI: doi:10.1358/dof.2010.035.012.1521419
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1838732314

Abstract

Oncolytic viruses are considered as a new class of therapeutic agents inducing preferential killing of malignant cells -both in cell culture and in animal models. In adult patients, clinical trials have mainly demonstrated the clinical safety of oncolytic virotherapy and, in some cases, promising effects against disease progression. The present publication is the first to review the application of any type of oncolytic virus to malignant diseases occurring exclusively or mainly in childhood. The first part gives an overview on the preclinical assessment of oncolytic virotherapy for the 15 most frequent pediatric malignancies. The second part of the article focuses on the specific issues raised by the clinical evaluation of oncolytic virotherapy in children suffering from cancer. In contrast to the extensive preclinical work, only four phase I-II clinical trials have included pediatric or adolescent patients, since clinical research on oncolytic viruses for pediatric patients has just entered the hospitals.